Plain-English translation of NCT06671496 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called (TAK-279) to see if it can help control psoriatic arthritis—a condition that causes joint pain and swelling in people with psoriasis. Researchers want to understand how well this medication works and how safe it is, particularly for people who have already tried other arthritis treatments without success.
Many people with psoriatic arthritis don't respond well enough to current treatments like NSAIDs, conventional disease-modifying drugs, or biologic medicines. This trial is testing whether the medication could offer a better option for these patients.
Participants will take a daily tablet by mouth for up to 52 weeks, with study visits lasting about 60 weeks total. Some participants will receive the new medication from the start, while others will receive a placebo (inactive pill) for the first 16 weeks and then switch to the medication. Researchers will regularly check your joints and skin to see how well the treatment is working.
AI-generated summary from trial data · Aug 18, 2026 · Not medical advice
United States